Biogen Inc. (BIIB) Stock Analysis
Latest ClaritX AI analysis ·
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio includes a range of medications addressing multiple sclerosis (MS), such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy (SMA), Biogen provides SPINRAZA, while FUMADERM is available for the treatment of plaque psoriasis. Among its other key offerings is ADUHELM, specifically developed for Alzheimer's disease. The company also markets a selection of biosimilar drugs, including BENEPALI (an etanercept biosimilar akin to ENBREL), IMRALDI (an
| Metric | Value |
|---|---|
| Price | $219.88 |
| Market cap | $32.5B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| ClaritX AI score | 88/100 |
| Price/Book | 1.72 |
| Beta | 0.17 |
AI verdict
Biogen Inc. (BIIB) remains a premier, highly cash-generative biotechnology anchor, fundamentally underpinned by an elite $20.10 in free cash flow per share and an incredibly cheap Price-to-Free-Cash-Flow multiple of 10.94. The company is actively validating its strategic pivot, with recent clinical data confirming that its newer growth portfolio—now bolstered by the highly promising Phase 2/3 litifilimab data for lupus—is successfully expanding beyond its legacy multiple sclerosis assets. Coupled with the critical Japanese regulatory approval of the subcutaneous LEQEMBI Pen, Biogen is structurally de-risking its pipeline. This operational excellence is corroborated by sustained, heavy corporate insider accumulation. Furthermore, Biogen's hyper-defensive beta of 0.171 effectively uncouples the asset from systemic macroeconomic volatility, allowing it to trade purely on the merits of its internal clinical execution. From a technical perspective, Biogen exhibits formidable strength and a vastly improved risk-reward profile, trading at $219.88, which places it just 4.60% below its absolute 52-week high of $230.49. Because the stock trades on idiosyncratic fundamental milestones, this proximity to the yearly zenith highlights true institutional conviction rather than euphoric market momentum. Crucially, the recent mild price retracement has successfully cooled the 14-day RSI to 53.90, firmly pulling the equity out of near-term momentum exhaustion. With a flawless 5/5 DCF valuatio
What this score has been worth
ClaritX scores BIIB 88 out of 100 (snapshot 2026-10-05).
Every ClaritX analysis is scored first and judged only on what the stock did afterwards. Across the 203 analyses that scored in the 85-89 band, the average forward return was +1.7% with a 52% win rate, -3.7pp against the S&P 500. That is a measured tendency across many names, not a forecast for BIIB — roughly 48% of stocks in this band still lost money.
The full band-by-band table, including the bands that lost, is on the AI Rank Report; the live strategy arms behind it are on the AI Track Record, losses published.